Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)

NCT02122003 is registered in ClinicalTrials.gov with Fondazione IRCCS Istituto Nazionale dei Tumori, Milano as lead sponsor.

NCT NCT02122003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02122003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Activity and Safety of Second Line SOrafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study)
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase
Phase 2
Overall status
Terminated
Start date
September 30, 2016
Completion date
November 8, 2017
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic renal cell carcinoma